Identification of a Two-Gene Biomarker Correlated with Sensitivity to Combined PARP7 Inhibition and AHR Activation in Cancer Cells
We employed a multiomic approach to identify a transcriptional biomarker that is predictive of cellular response to combined treatment with PARP7i and AHRa. The molecular, immune, and prognostic characterizations of this biomarker may provide insights into the molecular mechanisms of response and aid in stratifying patients likely to benefit from this combination therapy.
Authors
- Huadong Chen (ORCID: https://orcid.org/0000-0003-4681-0853)
- Morgan E. Diolaiti (ORCID: https://orcid.org/0000-0001-5900-3060)
- Xuxu Gou (ORCID: https://orcid.org/0000-0003-2318-778X)
- Alan Ashworth (ORCID: https://orcid.org/0000-0003-1446-7878)
Institutions
- University of California, San Francisco (US)
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2025-11-26
- DOI
- https://doi.org/10.1158/2767-9764.crc-25-0173
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Breast Cancer Research Foundation
- Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation
- Emerson Collective
- National Institutes of Health
- University of California, San Francisco